

Serial No.: 08/873,601
Filed: June 12, 1997

APPENDIX

1. (Amended) A cell containing a composition comprising:
 - a) an [exogeneous]exogenous scaffold having no enzymatic activity and comprising at least a first binding site and a second binding site; and
 - b) at least a first and a second enzyme, wherein at least one of said enzymes is heterologous to said cell;
wherein said first enzyme is bound to said first binding site and said second enzyme is bound to said second binding site.
2. (Amended) A cell containing a composition comprising:
 - a) nucleic acid encoding an [exogeneous]exogenous scaffold having no enzymatic activity and comprising at least a first binding site and a second binding site; and
 - b) nucleic acid encoding at least a first and a second enzyme, wherein at least one of said enzymes is heterologous to said cell;
wherein said first enzyme is capable of being bound to said first binding site and said second enzyme is capable of being bound to said second binding site.
3. A cell according to claim 1 or 2, wherein said scaffold comprises at least three binding sites.
4. A cell according to claim 1 or 2, wherein said scaffold comprises at least four binding sites.
5. A cell according to claim 1 or 2, wherein said scaffold comprises at least five binding sites.
6. A cell according to claim 1 or 2, wherein said binding sites are on the same scaffold molecule.
7. A cell according to claim 1 or 2, wherein said binding sites are on different scaffold molecules.
8. (Amended) A cell according to claim 1 or 2, further comprising
 - c) an [exogeneous]exogenous bioactive agent precursor.

Serial No.: 08/873,601
Filed: June 12, 1997

27. A cell according to claim 2, wherein said cell is a mammalian cell.
28. A cell according to claim 2, wherein said scaffold is linear.
29. A cell according to claim 2, wherein said scaffold is circular.
30. A cell according to claim 2, wherein said scaffold is branched.
31. A cell according to claim 1 or 2, wherein said scaffold further comprises a fusion partner.
32. A cell according to claim 1 or 2, wherein at least one of said enzymes further comprises a fusion partner.
33. A cell according to claim 31, wherein said fusion partner is a presentation structure.
34. A cell according to claim 31, wherein said fusion partner is a targeting sequence.
35. A cell according to claim 31, wherein said fusion partner is a rescue sequence.
36. A cell according to claim 31, wherein said fusion partner is a stability sequence.
37. A cell according to claim 31, wherein said fusion partner is a linker sequence.
38. A cell according to claim 32, wherein said fusion partner is a presentation structure.
39. A cell according to claim 32, wherein said fusion partner is a targeting sequence.
40. A cell according to claim 32 wherein said fusion partner is a rescue sequence.
41. A cell according to claim 32, wherein said fusion partner is a stability sequence.
42. A cell according to claim 32, wherein said fusion partner is a linker sequence.--